SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 117,390.87 |
| Enterprise Value ($M) | 159,347.87 |
| Book Value ($M) | 17,200.00 |
| Book Value / Share | 8.48 |
| Price / Book | 6.83 |
| NCAV ($M) | -48,395.00 |
| NCAV / Share | -23.86 |
| Price / NCAV | -2.43 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.11 |
| Return on Assets (ROA) | -0.08 |
| Return on Equity (ROE) | -0.25 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 1.09 |
| Current Ratio | 1.24 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 28,075.00 |
| Assets | 93,670.00 |
| Liabilities | 76,470.00 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Earnings Per Share Diluted | n/a |
| Earnings Per Share Basic | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Vanguard Group Inc | 9.74 | -2.35 | |
| 13G/A | BlackRock, Inc. | 8.30 | -2.68 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 762,552 | 6,113,551 | 12.47 | |
| 889,257 | 8,399,726 | 10.59 | |
| 1,835,123 | 10,106,114 | 18.16 | |
| 1,534,120 | 8,931,574 | 17.18 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| ANVS – Annovis Bio, Inc. | BHC – Bausch Health Companies Inc. |
| BHVN – Biohaven Ltd. | CTLT – Catalent, Inc. |
| EBS – Emergent BioSolutions Inc. |